PD-1 Targeted Antibody Discovery Using AI Protein Diffusion.
Technol Cancer Res Treat
; 23: 15330338241275947, 2024.
Article
in En
| MEDLINE
| ID: mdl-39228166
ABSTRACT
The programmed cell death protein 1 (PD-1, CD279) is an important therapeutic target in many oncological diseases. This checkpoint protein inhibits T lymphocytes from attacking other cells in the body and thus blocking it improves the clearance of tumor cells by the immune system. While there are already multiple FDA-approved anti-PD-1 antibodies, including nivolumab (Opdivo® from Bristol-Myers Squibb) and pembrolizumab (Keytruda® from Merck), there are ongoing efforts to discover new and improved checkpoint inhibitor therapeutics. In this study, we present multiple anti-PD-1 antibody fragments that were derived computationally using protein diffusion and evaluated through our scalable, in silico pipeline. Here we present nine synthetic Fv structures that are suitable for further empirical testing of their anti-PD-1 activity due to desirable predicted binding performance.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Programmed Cell Death 1 Receptor
/
Immune Checkpoint Inhibitors
Limits:
Humans
Language:
En
Journal:
Technol Cancer Res Treat
Journal subject:
NEOPLASIAS
/
TERAPEUTICA
Year:
2024
Document type:
Article
Affiliation country:
United States
Country of publication:
United States